Sodium-Glucose Cotransporter 2 Inhibitors and Urinary Tract Infection: Is There Room for Real Concern?
- 12 September 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (11) , 1991-1993
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have revolutionized our armamentarium for kidney and heart protection in patients with or without diabetes. Based on early reports of a limited number of cases, a concern for increased risk of urinary tract infections arose, which has become one of the main areas of concern for some clinicians. However, data from large randomized clinical trials and real-world population-based studies have not shown a significantly increased risk of UTI in patients on SGLT2 inhibitors. The goal of this brief review article is to review the literature and provide reassurance to patients and prescribers for the broader use of these agents.Keywords
This publication has 14 references indexed in Scilit:
- A hypothesis for why sodium glucose co‐transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infectionDiabetes, Obesity and Metabolism, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract InfectionsAnnals of Internal Medicine, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trialsActa Diabetologica, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Caution advised with dapagliflozin in the setting of male urinary tract outlet obstructionBMJ Case Reports, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015